# A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

> **NCT03707028** · PHASE1,PHASE2 · TERMINATED · sponsor: **Elevar Therapeutics** · enrollment: 12 (actual)

## Conditions studied

- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Rivoceranib
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03707028
- **Lead sponsor:** Elevar Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-01
- **Primary completion:** 2021-08-24
- **Final completion:** 2021-08-24
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Terminated after completion of Part 1 due to a change in research plan.
- **Last updated:** 2022-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03707028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03707028, "A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03707028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*